Virios Therapeutics

Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Virios Therapeutics advances Long-COVID treatment, seeks strategic partnerships

Virios Therapeutics is on track with its Long-COVID Phase II study, showing promising results and a clear path towards value creation.
The company's focus on intellectual property protection and partnership development positions it well for long-term growth and innovation in the healthcare sector.
While facing challenges in study outcomes and partnership acquisitions, Virios remains proactive in seizing opportunities to enhance shareholder value and expand its treatment portfolio.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

ATLANTA--(BUSINESS WIRE)--Interview with Chairman and CEO of Virios Therapeutics, Inc. to Air on Bloomberg Television on the RedChip Money Report

Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman and Chief Executive Officer, and R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer, will present a company overview at the Needham Virtual Healthcare Conference on April 14, 2021 at 4:30 p.m. ET. The presentation

Virios Therapeutics to Present at the Needham Virtual Healthcare Conference

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update. “Since our initial public offering in December 2020, the Virios Therapeutics team has made significant operational progress to ensure the c

Virios Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

The company believes that an abnormal immune response to Herpes Simplex Virus 1 (HSV-1) infection is responsible for chronic conditions like FM and IBS, representing a novel mechanism of action. There is currently no significantly effective treatment for 3.6M diagnosed FM patients.

Virios Therapeutics: Highly Differentiated Mechanism Of Action In Fibromyalgia

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that its fourth quarter and full year 2020 financial results will be reported on Thursday, March 18, 2021 before the open of the financial markets. Management will also host a webcast and conference call on March 18, 2021 at 8:30 a.m. ET to disc

Virios Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Thursday, March 18, 2021

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Life Sciences Conference, which is taking place March 9 - 10, 2021. The presentation will focus on the need for new approaches

Virios Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in March 2021

Brown & Brown

Sierra Bancorp

Chemung Financial

Cyclo Therapeutics, Inc.

Fastenal

Surgalign Holdings, Inc.

Insider buying could be a bullish signal for a stock. Why? The insiders may sell for a number of reasons.

7 Stocks With Insider Buying

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS). The first step in the collaboration is focused on designing a phase 2 proof of concept study to tre

Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the virtual 2021 BIO CEO & Investor Conference to be held from February 16-18, 2021. The presentation will focus on the need for new approaches to treat fibromyalgia (“FM”

Virios Therapeutics to Present at the BIO CEO & Investor Conference

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (VIRI) will present at the H.C. Wainwright Virtual BioConnect Conference, taking place January 11-14, 2021.

Virios Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, today announced the closing of its initial public offering of 3,450,000 shares of its common stock at a public offering price of $10.00 per share, which includes 450,000 shares sold upon full exercise of the underwriter's option to purchase additional common shares. The gross proce

Virios Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-Allotment Option

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (the “Company”), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $30 million, before deducting underwriting discounts, commissions and offering expenses. In addition, the Compan

Virios Therapeutics Announces Pricing of Initial Public Offering

News for Virios Therapeutics Stock (VIRI)